oropharynx cancer (Cancer)
Information
- Disease name
- oropharynx cancer
- Disease ID
- DOID:8557
- Description
- "A pharynx cancer that is located_in the oropharynx." [url:http\://www.cancer.gov/dictionary?CdrID=446523]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03082534 | Active, not recruiting | Phase 2 | Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma | March 28, 2017 | May 2024 |
| NCT03874572 | Active, not recruiting | Phase 1 | Allogeneic Mesenchymal Stem Cells for Radiation-induced Hyposalivation and Xerostomia/Dry Mouth | March 18, 2019 | December 1, 2025 |
| NCT03174275 | Active, not recruiting | Phase 2 | Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma | December 19, 2017 | February 2, 2027 |
| NCT04638465 | Active, not recruiting | De-Escalation Protocol Of HPV Mediated Oropharyngeal Squamous Cell Carcinoma | August 6, 2018 | January 2030 | |
| NCT04609280 | Active, not recruiting | Phase 2 | Selective Avoidance of Nodal VolumEs at Minimal Risk (GCC 20110) | March 1, 2021 | December 2026 |
| NCT02586207 | Active, not recruiting | Phase 1 | Pembrolizumab in Combination With CRT for LA-SCCHN | November 2015 | September 2024 |
| NCT03838263 | Active, not recruiting | Phase 2 | Feasibility and Tolerance of Nivolumab Neoadjuvant Immunotherapy in High Risk HPV Driven Oropharynx Cancer | July 25, 2019 | November 2024 |
| NCT03416153 | Active, not recruiting | Phase 2 | Individualized Adaptive De-escalated Radiotherapy for HPV-related Oropharynx Cancer | May 21, 2018 | May 2024 |
| NCT02908477 | Active, not recruiting | Phase 3 | Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus (HPV)-Associated Oropharynx Cancer | October 3, 2016 | September 15, 2024 |
| NCT03418909 | Active, not recruiting | Functional Outcome After Treatment for Oropharyngeal Squamous Cell Carcinoma | April 1, 2017 | June 30, 2024 | |
| NCT05904327 | Active, not recruiting | Circulating Biomarkers in Oropharyngeal Cancers | December 1, 2020 | March 31, 2028 | |
| NCT03342378 | Completed | PET-MRI Assessment of Early Tumor Response to Predict Outcomes of HPV-Positive Oropharynx Cancer Patients | May 3, 2018 | May 15, 2021 | |
| NCT03418792 | Completed | N/A | Functional Sparing of Salivary Glands Using MRI Sialography for Patients Undergoing Definitive Radiation Therapy for Head and Neck Cancers of the Oropharynx | March 8, 2018 | May 2, 2023 |
| NCT03435471 | Completed | N/A | Outcomes of Prophylactic Swallowing Therapy in Patients Undergoing Definitive Chemoradiation for Head and Neck Cancer | September 17, 2018 | January 13, 2021 |
| NCT01173692 | Completed | Phase 2 | Minocycline for Reduction of Radiation Therapy Treatment-Related Symptom Burden in Oropharynx Cancer: A Randomized Study. | July 22, 2010 | July 7, 2020 |
| NCT00158652 | Completed | Phase 3 | Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC | March 2000 | March 2011 |
| NCT00158678 | Completed | Phase 3 | IMRT Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Stage III-IV HNSCC | September 27, 2005 | March 22, 2020 |
| NCT00162708 | Completed | Phase 2/Phase 3 | Very Intense Radiotherapy-Chemotherapy Regimen in Advanced HNSCC | July 1996 | |
| NCT01108042 | Completed | Phase 1/Phase 2 | TPF-Induction Chemotherapy of Oropharyngeal and Cavity of the Mouth Cancer | November 2009 | February 2016 |
| NCT01874587 | Completed | Phase 3 | Adaptative Radiotherapy to Decrease Xerostomia in Oropharynx Carcinoma | July 2013 | December 8, 2020 |
| NCT02365844 | Completed | Multispectral Imaging to Characterize Patterns of Vascular Supply Within Lymphoepithelial Mucosa in Oropharyngeal Cancer | February 2015 | August 27, 2018 | |
| NCT02981862 | Completed | N/A | CaptHPV : Validation of the Method "CaptHPV" for the Diagnosis of Human Papillomavirus Associated Infiltrating Carcinomas | December 19, 2016 | June 12, 2018 |
| NCT03096808 | Completed | Phase 2 | Adaptive Radiotherapy for Head and Neck Cancer | March 15, 2017 | October 22, 2021 |
| NCT03226613 | Completed | N/A | New Modalities for Detection of Oropharyngeal Cancer | August 15, 2017 | June 6, 2018 |
| NCT03269344 | Completed | Phase 3 | Gabapentin for the Reduction of Radiation Therapy Induced Pain During the Treatment of Oropharyngeal Cancer | June 5, 2017 | December 9, 2020 |
| NCT04112940 | Completed | Physiological Flow of Liquids in Head and Neck Cancer Patients: A Pilot Study | December 19, 2016 | March 30, 2021 | |
| NCT04567082 | Completed | Proteome- and Methylation Profiles in Oropharyngeal Cancer | September 25, 2020 | January 31, 2024 | |
| NCT05025618 | Completed | Adaptative Radiotherapy to Decrease Xerostomia in Oropharynx Carcinoma (ARTOME) | July 5, 2013 | December 8, 2020 | |
| NCT05055206 | Completed | N/A | Study of Lymphatic Drainage Mapping in Oropharyngeal Cancers | September 13, 2021 | October 31, 2023 |
| NCT05368025 | Completed | Staying Connected: a Mobile Health Study With the Noona® and Mobili-T® Systems | February 17, 2022 | May 26, 2023 | |
| NCT05698667 | Completed | N/A | Outpatient Ultrasound for the Diagnostic Work-up of Oropharynx Cancer | October 1, 2021 | May 1, 2022 |
| NCT05849142 | Not yet recruiting | N/A | Feasibility of Adaptive Radiation Therapy for Human-papilloma Virus-positive Oropharyngeal Cancer Patients on MRIdian Linac | July 1, 2024 | December 1, 2024 |
| NCT06276946 | Not yet recruiting | N/A | Sparing Parotid Ducts Via MRI Sialography for Reduced Patient Reported Xerostomia | August 8, 2024 | January 2029 |
| NCT06309225 | Not yet recruiting | N/A | Dose Adjusted Chemoradiotherapy in HPV-Associated Oropharynx Cancer of the Elderly | March 30, 2024 | June 1, 2026 |
| NCT05639972 | Not yet recruiting | Phase 1/Phase 2 | E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers | June 12, 2024 | October 1, 2026 |
| NCT06088381 | Recruiting | Phase 2 | Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL) | March 7, 2024 | October 18, 2027 |
| NCT04667585 | Recruiting | N/A | Radiotherapy Dose De-escalation in HPV-Associated Cancers of the Oropharynx | April 12, 2021 | April 2027 |
| NCT04901234 | Recruiting | Phase 2 | Adaptive RadioTherapy for OroPharynx Cancer | July 30, 2021 | December 2026 |
| NCT06100081 | Recruiting | N/A | Real-time Targeted Fluorescence Endoscopy for Detection of the Primary Cancer Lesion in Patients With a Metastasis of Unknown Primary Tumor in the Head and Neck | April 28, 2023 | December 31, 2025 |
| NCT06234748 | Recruiting | Phase 2 | Trial of Individualized Adaptive RT in HPV-related High Risk Oropharynx Cancer | December 20, 2023 | July 2026 |
| NCT05211427 | Recruiting | N/A | Bitter Taste Receptors in Oropharynx Cancer | March 23, 2021 | July 2025 |
| NCT05307939 | Recruiting | Phase 2 | A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC) | March 24, 2022 | March 24, 2025 |
| NCT05337631 | Recruiting | Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy | June 1, 2021 | December 31, 2023 | |
| NCT04124198 | Recruiting | N/A | Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma | March 1, 2019 | January 2029 |
| NCT04277858 | Recruiting | Phase 2 | Neoadjuvant Chemotherapy and Transoral Robotic Surgery for Oropharyngeal Cancer. | August 14, 2018 | August 30, 2026 |
| NCT04359199 | Recruiting | QUantitative Assessment of Swallowing After Radiation (QUASAR) | September 1, 2020 | December 31, 2024 | |
| NCT04444869 | Recruiting | Phase 2 | Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer | September 28, 2020 | June 2026 |
| NCT05787639 | Recruiting | Phase 2 | Neoadjuvant Immunoradiotherapy With Evorpacept and Pembrolizumab in HPVOPC (Human Papilloma Virus Oropharynx Cancer) | February 20, 2024 | May 30, 2028 |
| NCT05793151 | Recruiting | N/A | Multi-Site Trial of Navigation vs Treatment as Usual for Delays in Starting Adjuvant Therapy | October 30, 2023 | March 30, 2028 |
| NCT05798780 | Recruiting | N/A | The ENHANCE Study: Exercise and Nutrition in Head And Neck CancEr Survivors | April 6, 2023 | January 2025 |
| NCT05800574 | Recruiting | Phase 2 | Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Favorable Risk Oropharynx Cancer | March 14, 2023 | September 23, 2026 |
| NCT03383094 | Recruiting | Phase 2 | Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer | March 15, 2018 | June 2025 |
| NCT03942380 | Recruiting | N/A | Cell-free Tumor DNA in Head and Neck Cancer Patients | February 1, 2017 | February 1, 2025 |
| NCT06016699 | Recruiting | Immunological Function After Radiation With Either Proton or Photon Therapy | September 23, 2021 | April 1, 2024 | |
| NCT04178174 | Recruiting | Phase 2 | Stereotactic Boost and Short-course Radiation Therapy for Oropharynx Cancer | February 23, 2020 | December 2026 |
| NCT05369234 | Recruiting | Phase 3 | Effects of Oral Aloe Vera Juice on Chemotherapy and Radiation-induced Oral Mucositis and Esophagitis | January 20, 2022 | January 30, 2024 |
| NCT05388773 | Recruiting | Phase 2 | Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer | July 20, 2022 | June 2030 |
| NCT05686226 | Recruiting | Phase 2 | E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers | March 7, 2023 | January 1, 2025 |
| NCT05696314 | Recruiting | N/A | Surgeon-performed Outpatient Transoral and Transcervical Ultrasound of the Oropharynx | January 31, 2023 | February 1, 2025 |
| NCT05757817 | Recruiting | N/A | Evaluation of the Benefit of a New Surgical Procedure According to IDEAL Recommendations for ORL Cancer Patients: the External Pudendal Flap Used as a New Free Flap for Oral Cavity/Oropharyngeal Reconstruction to Limit Donor Site Sequelae | November 8, 2023 | January 2027 |
| NCT01066741 | Terminated | Phase 3 | Prevention of Radiation-induced Severe Oral Mucositis in Oral Cavity, Oropharynx, Hypopharynx, and Cavum Cancer | May 2009 | August 2011 |
| NCT00080028 | Terminated | Phase 1 | Motexafin Gadolinium With Chemotherapy and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer | ||
| NCT04301011 | Terminated | Phase 1/Phase 2 | Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors | June 2, 2020 | January 23, 2023 |
| NCT00537199 | Terminated | Phase 3 | OraTest in Combination With Visual Examination and Visual Examination Alone | November 2006 | December 2008 |
| NCT00232960 | Unknown status | N/A | Postoperative Radiotherapy According to Molecular Analysis of Surgical Margins of Oral and Oropharyngeal SCC | October 2005 | June 2014 |
| NCT04892875 | Withdrawn | Phase 1 | A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers | December 31, 2023 | December 2026 |
| NCT04001413 | Withdrawn | Phase 2 | Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients | September 17, 2019 | March 25, 2021 |
| NCT05535023 | Withdrawn | Phase 2 | Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell Carcinoma | August 24, 2022 | July 25, 2023 |
- Disase is a (Disease Ontology)
- DOID:0060119
- Cross Reference ID (Disease Ontology)
- ICD10CM:C10
- Cross Reference ID (Disease Ontology)
- ICD10CM:C10.2
- Cross Reference ID (Disease Ontology)
- ICD10CM:C10.3
- Cross Reference ID (Disease Ontology)
- ICD10CM:C10.8
- Cross Reference ID (Disease Ontology)
- ICD9CM:146
- Cross Reference ID (Disease Ontology)
- ICD9CM:146.5
- Cross Reference ID (Disease Ontology)
- ICD9CM:146.6
- Cross Reference ID (Disease Ontology)
- ICD9CM:146.7
- Cross Reference ID (Disease Ontology)
- NCI:C7398
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:187686007
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:93933005
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:93971002
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0153382
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0153388
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0153389
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0153390
- Exact Synonym (Disease Ontology)
- malignant Oropharyngeal tumor
- Exact Synonym (Disease Ontology)
- malignant tumor of oropharynx
- Exact Synonym (Disease Ontology)
- malignant tumour of mesopharynx
- Exact Synonym (Disease Ontology)
- oropharyngeal cancer
- Exact Synonym (Disease Ontology)
- Oropharyngeal carcinoma